The treatment of advanced thyroid cancer is currently entering a new era due to the introduction of targeted therapy into modern cancer treatment. The growing insight into the molecular biology of thyroid cancer and on the development of numerous mainly multitargeted agents provide the basis for new treatment strategies. In particular, activation of mitogenic and angiogenic signalling pathways are suitable targets as preclinical and clinical data suggest. Several Phase II and a few Phase III studies were launched in thyroid cancer which included medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC) but only a few focused specifically 
Medullary Thyroid Cancer

Prognosis and Standard Treatment
Patients age and extent of disease at the time of diagnosis are the main independent indicators for disease relapse and mortality in MTC. The preoperative level of calcitonin is capable to predict the probability for disease-free survival. 11 Post-surgery, if calcitonin is beyond the detection level after pentagastrin stimulation, patients are likely to be free of disease. 5 However, incomplete remission of calcitonin after initial surgery does not rule out long-term survival. 5 Mutation analysis of the RET proto-oncogene identified a specific activating point mutation, M918T
which appears to be a strong negative prognostic indicator for progression-free survival (PFS) and OS (OS). 12 The presence of this mutation reduces the 10-year survival by half from about 90 to 45 %. 12 Patients with RET germline mutations characteristic of the multiple endocrine neoplasia (MEN) type 2A and B syndrome are at extreme risk to develop MTC and preventive total thyroidectomy is recommended. 13 In hereditary or sporadic MTC total thyroidectomy combined with lymph node dissection of central compartments is considered the cornerstone of the primary treatment. The additional lateral lymph node dissection is usually indicated in hereditary MTC but should be performed in sporadic MTC only if lymph node metastases are suspected or dependent on the stimulated calcitonin level prior to surgery. 14, 15 Two to three months following primary resection, calcitonin drops below the detection level in 60-90 % of patients without lymph node involvement. 6 Persistence of calcitonin indicates residual disease and there seems to be a correlation between the level of calcitonin and the remaining tumour burden. 6 In the event of residual disease or disease relapse with tumour mass in the neck or mediastinum, re-operation is usually performed. However, the definitive cure rate is reported to be less than 40 % in this situation. 6 In patients with localised disease with either elevated calcitonin, microscopic residual disease or positive lymph nodes, external beam radiation was shown to reduce the risk of loco-regional tumour recurrence. 16, 17 The main cause of disease-related death are distant metastases which often affect multiple organs including mainly lung, bone and liver. 6 The occurrence of distant metastases considerably affects survival rates which decline at five years to 25 % and at 10 years to 10 %, respectively. 6 In this palliative setting, the relief of symptoms and maintenance of quality of life are the major treatment goals. Calcitonin-induced diarrhoea may temporarily be controlled by either loperamide or somatostatin analogues. Beside the improvement of symptoms, somatostatin analogues alone or in combination with interferon have some efficacy to reduce serum calcitonin levels but rarely induce substantial tumour remissions. 18 Beside the application of bisphosphonates, surgery, external beam radiation or chemoembolisation may be useful to treat bone metastases. 6 In case of clinically dominant liver metastases, chemoembolisation might be effective to reduce tumour burden and provide symptomatic relief. 19 The effect of chemotherapy on OS is unclear due to the lack of large-scale clinical trials and until recently has been considered for the palliation of symptoms in metastatic disease particularly at the time of rapid tumour progression. 5, 6 Transient tumour responses in up to 20 % have been observed with doxorubicin or aclarubicin alone.
Symptomatic improvement and response rates similar to doxorubicin were observed with combinations of 5-fluorouracil/dacarbacin or 5-fluorouracil/streptocotocin. 5 However, in the light of the promising data for molecular treatment approaches a critical re-appraisal of the value of conventional chemotherapy is warranted.
Anaplastic Thyroid Cancer
Prognosis and Current Treatment
ATC usually manifests itself as a rapidly enlarging anterior neck mass with a doubling time of tumour volume sometimes of less than two weeks. This is often accompanied by dysphagia, dyspnoea or vocal cord paralysis. 20 In most of the cases, ATC is locally advanced, frequently unresectable and about 50 % of patients have metastatic disease at diagnosis. 20 Prognostic parameters are age, sex, size of the primary tumour, complete resection and extent of the disease.
21,22
Sugitani et al. defined a prognostic score which is based on the following risk factors: acute symptoms, tumour >5 cm, presence of distant metastases and white cell count >10,000 μl. 23 As most of the patients die due to local tumour complications within a few month after diagnosis, improving the local disease control might potentially extend the OS. 8, 24 While the treatment standard is still evolving, results from different retrospective studies suggested that single modality treatment is usually insufficient to achieve this goal. 21, 25 Multimodality treatment of ATC typically includes surgery, radiotherapy and chemotherapy. Based on recent clinical data it appears that only a combined treatment approach may improve the clinical outcome in terms of both local and systemic disease control. 8, 24 The goal of curative surgery is to completely resect the tumour. In fact, a complete tumour resection was recently identified as a prognostic factor in clinical trials in ATC. Moreover, if potentially curative surgery is combined with post-operative adjuvant radiotherapy, this could result in a significantly increase in OS. 26, 27 Given the overall still dismal prognosis, however, surgery should usually be limited to not compromise the functional anatomy of the cervical structures.
Radiation therapy could either be applied as hyperfractionated radiation alone or in combination with chemotherapy as radiosensitiser. The most commonly used drugs for radiochemotherapy are doxorubicin or mitoxantrone. 7 Radiotherapy combined with chemotherapy appeared to result in an improved OS as compared to radiotherapy alone. 28 More recent studies evaluated the curative potential of different radiation doses and data revealed that a hyperfractionated radiation regimen seems more effective than conventional treatment and that doses
Targeted Drugs in the Treatment of Advanced Medullary and Anaplastic Thyroid Cancer Hundahl et al., 1998. 70 above 45-50 Gy should be administered in order to achieve tumour control. 29 A retrospective analysis of patients treated at MD Anderson revealed no differences in toxicity between intensity modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3DRT). 30 By increasing the local tumour control rate, distant metastasis become a more important determinant of OS. 8 Consequently, systemic chemotherapy is frequently used to reduce that risk. Long-term survival in ATC was only observed in patients who were treated with a combined approach using surgery, radiation and chemotherapy. 7, 21, 22, 24, 33 However, the optimal sequence of the available treatment modalities is still a matter of debate. 8 In several studies surgery is used as first line treatment in resectable cases, followed by either radiation or radiochemotherapy. 20, 21, 26, 31, [34] [35] [36] In more recent studies neoadjuvant radiation or radiochemotherapy preceding surgery and with increased dose from <30 Gy to hyperfractionated doses between 45 and 60 Gy was investigated. 7, [37] [38] [39] These studies also showed that complete local tumour resection with this multimodality approach is a strong predictor for long term survival. Pre-operative radiation or radiochemotherapy might be advantageous, since it may enhance operability. In addition, surgical biopsy or attempted resection might delay the initiation of further local therapy due to poor wound healing which also favours pre-operative radiation or radiochemotherapy. However, randomised, prospective clinical trials would be necessary to finally clarify the question of the optimal sequence of multimodality treatment.
Molecular Targets in Thyroid Cancer
Targeted agents, focused on inhibition of molecular pathways, are expanding treatment options for patients with a broad spectrum of tumours. Advancing knowledge of the molecular pathogenesis of thyroid cancer and the precise characterisation of potential molecular targets for therapy has led to an increasing number of targeted drugs that are currently being explored in thyroid cancer in vitro and in vivo ( Figure 2 and Tables 1-3 ). As a result of intense research, several agents have been and currently are investigated in clinical trials and some of them demonstrate significant activity (see Table 3 ). Most of these drugs RET gene with tumourigenic potential were described. 6 Mutated RET provides mitogenic and survival signals and some specific activating point mutations like M918T appear to be strong negative prognostic indicators for metastasis free survival and OS. 12 Thus it is logical to target RET as a key driving element of MTC.
In familial MTC, loss of heterozygosity in the von Hippel-Lindau (VHL) disease tumour suppressor locus at the somatic level has been described and might be associated with progression of MTC.
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Furthermore, chromosomal imbalance with partial or complete loss of Thyroid Disorders Potential Targets in Anaplastic Thyroid Cancer Table 2) . 27 Based on microarray data, it was recently suggested that PDGFR is overexpressed in ATC relative to well differentiated thyroid cancers. Furthermore, it was found to be upregulated in tumours with either mutant or deficient p53. Thus, agents with combined targeting activity against PDGFR and cABL might be promising in ATC. Table 2 ). In several of these Phase II and Phase III studies the therapeutic agents exerted a considerable amount of partial responses and a large proportion of prolonged disease stabilisation (see Table 3 ).
The two main signalling pathways for tyrosine kinase (TK) receptors like vadcular endothelial growth factor-receptor (VEGF-R) or epidermal growth factor-receptor (EGF-R) are the Ras-Raf-mitogen-activated protein kinase (MAPK) pathway and the phosphoinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR)-pathway. These pathways regulate the phosphorylation status of nuclear transcription factors and thereby regulate cellular proliferation, survival and differentiation. The figure illustrates the main drugs that act along these signal transduction pathways as well as inhibitors of aurora kinases (PF03814735, VX-680) and histone-deacetylase (SAHA). The line with a square indicates inhibition, the rhomb indicates stabilisation. FGF-R = fibroblast growth factor-receptor; GDNF = glial cell line-derived neutrophic factor; HGF = hepatocyte growth factor; HSP90 = heat shock protein 90; IGF-R = insulin-like growth factor-receptor; PDGFR = platelet-derived growth factor-receptor.
Interestingly, activity in MTC was observed not exclusively for agents with designated RET inhibitory activity but also for TKIs without RET inhibitory capacity. This suggests that besides targeting RET other targets like the VEGF system are clinically relevant targets for the treatment of MTC.
In the first large-scale randomised, placebo-controlled Phase III study in MTC, vandetanib met the primary study objective and significantly prolonged the PFS. 40 At present, no final data are available yet since the survival data are still maturing and median PFS is not reached at 24-month follow-up. However, the available data were sufficient for the FDA to grant approval to vandetanib as an orphan drug for the treatment of metastatic or progressive irresectable MTC in April 2011.
Other multi TKIs like sorafenib, axitinib or sunitinib were tested in Phase II trials in thyroid cancer including cases with MTC. Overall, these drugs induced remissions and led to stable disease at a similar rate as vandetanib in 54, 55 (see Table 3 ).
In contrast, two studies evaluating the activity of imatinib, an oral TKI of BCR-Abl and KIT, reported no objective response and only a few patients achieved disease stability. 56 Three patients discontinued the The combined MET, RET and VEGFR2 inhibitor cabozantinib (XL184)
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exerted meaningful activity in a recent Phase I study including 37 patients with MTC. Twenty-nine per cent confirmed PR and 41 % disease stabilisation lasting for more than six months prompted the launch of the current randomised Phase III study in MTC. 58 Response data from a recent Phase I trial of lenvatinib (E7080) prompted the launch of a Phase II study in patients with MTC and refractory DTC. with ATC as a single agent. There was no objective response but some disease stabilisation (see Table 3 ). 62 Based on reported synergy of fosbretabulin and chemotherapy in pre-clinical studies, a Phase II study assessing the combination of fosbretabulin with a regimen of paclitaxel and carboplatin was initiated. Of the 80 patients included, 75 received therapy. A median survival time of 5.2 months was reported for the combination arm opposed to four months for the standard arm.
With a relative reduction in the risk of death by 35 % the one year, survival was 27 % in the combination arm versus 9 % in the standard arm. 63 In a recent Phase II study by Cohen et al. exploring the activity of the TKI axitinib in thyroid cancer, two patients with ATC were included. Axitinib exerted activity in all histological subtypes including one patient with ATC which experienced a partial remission. 64 In a Phase II study, Nagaiah et al. explored the activity of the broad spectrum TKI sorafenib in 15 patients with ATC. 65 Overall, a disease control rate of approximately 40 % was observed including two partial responses (see Table 3 ). However, time to progression and median OS were not encouraging with 1.9 and 3.5 months respectively. Despite the short PFS and median OS reported, the one year survival was 25 % after treatment initiation. 65 Following initial reports of relatively high response rates of sorafenib observed by Nagaiah, other studies reported more discouraging results. 66, 67 In thyroid cancer, inhibition of tumour-related angiogenesis and BRAF inhibition are of potential therapeutic value and thus it is unclear, whether the observed benefit of the VEGFR1-3 and BRAF-inhibitor sorafenib treatment is related to inhibition of BRAF-kinase or disruption of angiogenesis. In fact, particularly BRAF V600E mutation is associated with higher rate of lymph node metastases and higher TNM stage as well as increased VEGF-expression. 48, 60 This would favour a combined VEGF and BRAF inhibitory approach particularly for patients with proven BRAF V600E mutation. Thyroid Disorders Targeted Drugs in the Treatment of Advanced Medullary and Anaplastic Thyroid Cancer
and 4/8 achieving stable disease. 51 Further studies to explore the activity of imatinib in ATC seem to be warranted.
PPAR-γ is a member of a superfamily of nuclear hormone receptors, which were recently found to be overexpressed in ATC cell lines. For all involved in thyroid cancer research and treatment it is an inspiring time and it is clear that we indeed are witnessing a new era in the treatment of thyroid cancer. n
